• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Abbott to separate into two companies

Abbott to separate into two companies

October 19, 2011
CenterWatch Staff

Abbott has announced plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals.

The diversified medical products company will consist of Abbott's existing diversified medical products portfolio, including its branded generic pharmaceutical, devices, diagnostic and nutritional businesses, and will retain the Abbott name. The research-based pharmaceutical company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics and will be named later.

"Today's news is a significant event for Abbott, and reflects another dynamic change in our company's 123-year history, strengthening our outlook for strong and sustainable growth and shareholder returns," said Miles D. White, chairman and CEO of Abbott.

Abbott's proprietary pharmaceutical business has built a sustainable mix of products and a pipeline of proprietary medicines through internal discovery, in-licensing and collaboration efforts. Abbott’s diversified businesses include established pharmaceuticals, nutritionals, diagnostics and vascular devices.

The research-based pharmaceutical company currently has nearly $18 billion in annual revenue and will have a sustainable portfolio of market-leading brands. A pipeline of R&D assets in specialty therapeutic areas such as Hepatitis C, immunology, chronic kidney disease, women's health, oncology and neuroscience will help drive growth.

The diversified medical products company currently has approximately $22 billion in annual revenue and a mix of products balanced across four major businesses. It will target opportunities for geographic expansion, particularly in high-growth emerging markets. The company will have a broad-based pipeline of new products and technologies.

White will remain chairman and CEO of Abbott, the diversified medical products company. Richard A. Gonzalez, currently executive vice president, global pharmaceuticals, will become chairman and CEO of the research-based pharmaceutical company. Gonzalez is a 30+-year Abbott veteran and previously was Abbott president and COO.

The two companies have evolved into distinct investment and business opportunities. The research-based pharmaceutical company will focus on select specialty products with breakthrough innovation that serve patient needs in some of the most critical medical areas, such as immunology, Multiple Sclerosis, chronic kidney disease, Hepatitis C, women's health and oncology. This company will continue to generate the majority of its revenue from developed markets. The company's portfolio and pipeline, including established biologics expertise, have the potential to deliver accelerating revenue growth.

The diversified medical products company will be a large and fast-growing investment opportunity with a broad mix of products addressing many essential areas of health care. It will generate nearly 40% of its sales in high-growth emerging markets, with further expansion expected in the coming years.

The transaction is intended to take the form of a tax-free distribution to Abbott shareholders of a new publicly traded stock for the new pharmaceutical company. It is expected that the two companies will each pay a dividend that, when combined, will equal the current Abbott dividend at the time of separation. The transaction is expected to be completed by the end of next year, and is subject to final approval by the Abbott board of directors, receipt of a favorable ruling from the IRS on the tax-free nature of the transaction and the effectiveness of a Form 10 registration statement to be filed with the SEC.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing